

# OPTICAL SPECTROSCOPY OF HUMAN SKIN - TOOL FOR CANCER DETECTION IN VIVO

E. Borisova<sup>1</sup>, E. Pavlova<sup>2</sup>, P. Troyanova<sup>2</sup>, M. Kermedchiev<sup>2</sup>, N. Penkov<sup>2</sup>, T. Kundurjiev<sup>3</sup>,  
P. Pavlova<sup>4</sup>, A. Zhelyazkova<sup>1</sup>, Ts. Genova<sup>1</sup>, L. Avramov<sup>1</sup>

1) Institute of Electronics, Bulgarian Academy of Sciences, Sofia, Bulgaria

2) University hospital “Queen Jiovanna-ISUL”, Sofia, Bulgaria


3) Faculty of Public Health, Medical University-Sofia, Sofia, Bulgaria

4) Technical University – Sofia, branch Plovdiv, Plovdiv, Bulgaria




# Statistics of skin cancer

- Skin cancer is the **second most common cancer** - approximately 10 % of new cases. MMs are about 10-12 % from all cites, and about 90 % of skin cancer mortality rate.
- According WHO - currently, between 2,5 and 3 million non-melanoma skin cancers and 130,000 melanoma skin cancers occur globally each year. One in every three cancers diagnosed is a skin cancer, according to Skin Cancer Foundation Statistics.



## Individual risk factors for skin cancer

- fair skin
- blue, green or hazel eyes
- light-coloured hair
- tendency to burn rather than suntan
- history of severe sunburns
- many moles or/and freckles
- a family history of skin cancer





\* Cancer Research UK - <http://info.cancerresearchuk.org/cancerstats/faqs/#How>


\*\* ed. Sh.Danon, Zdr.Valerianova, Tzv.Ivanova, Cancer incidence in Bulgaria, Vol. XVI, 2013, National Oncological Centre, Bulgarian National Cancer Registry.

# Used diagnostic modalities

- **Dermatoscopy** – combined *in vivo* microscopic investigation with optical clearing of the epidermis
- **Ultrasound** – evaluation of lesion thickness and structures of tumors and foreign bodies
- **NMR** – information about tissue metabolism – intracellular pH, biochemical changes in cutaneous layers, hydrogenation, skin aging
- **Doppler diagnostics** – monitoring of vascular changes during pathology development, UV-radiation, vaso-active drugs and cosmetic products



\*




\*\*



# Skin cancer types

- **Basal cell carcinoma (BCC)** ~75 % of the cases – more than 10 subtypes - nodular, cystic, morpheaform, infiltrative, micronodular, superficial, pigmented, polypoid, pore-like, aberrant BCC
- **Squamous cell carcinoma (SCC)** ~ 15 % of the cases – several subtypes – Signet-ring cell, Clear cell, Adenoid, Basaloid SCC
  - **Keratoacanthoma (KA)** – several subtypes - giant, multiple, generalized eruptive, subungual keratoacanthoma, and keratoacanthoma centrifugum marginatum
- **Melanoma** ~ 10% of the cases
- Uncommon kinds of skin cancer - dermatofibrosarcoma protuberans, Merkel cell carcinoma, Kaposi's sarcoma, spindle cell tumors, sebaceous carcinomas, microcystic adnexal carcinoma, atypical fibroxanthoma, etc.



**3 major types, about 10 rare types, more than 20 sub-types**



**+ dysplasia**




**+ benign**



# Skin tumours diagnosis – human factor

## Comparison of Surface microscopy diagnoses before and after the training course

Diagnostic Indicator	Before	After
SENS (%)	65.00	71.56
SPEC (%)	80.93	79.69
DA (%)	54.59	59.48



Heamangioma



Base-cell  
papilloma

Dermatoscopic pictures of different skin lesions, magnification x100



Pigmented  
BCC



Malignant  
melanoma

## Comparison of Epiluminescence microscopy diagnoses before and after the training course


Diagnostic Indicator	Before	After
SENS (%)	75.31	89.69
SPEC (%)	83.44	83.12
DA (%)	62.92	77.74

# Optical spectroscopy of human skin

---

- Objective
- Real-time
- Non-invasive
- Highly sensitive
- Repeatable results
- Biochemical and morphological correlations
- Multiple applications
- Monitoring of therapeutic procedures
- High diagnostic accuracy
- Exclude human factor



# Light-skin interactions




Endogenous fluorophore	Excitation (nm)	Emission (nm)
<b><i>Amino acids</i></b>		
<i>Phenylalanine</i>	260	280
<i>Tyrosine</i>	275	300
<i>Tryptophan</i>	280	350
<b><i>Structural proteins</i></b>		
<i>Collagen</i>	280, 320-350, 390	370 - 440
<i>Elastin</i>	290 - 325	340, 400
<i>Collagen cross-links</i>	380 - 420	440 - 500
<i>Elastin cross-links</i>	320 - 360, 400	480 - 520
<i>Keratin</i>	380 - 400, 450 - 470	500 - 550
<b><i>Enzymes and co-enzymes</i></b>		
<i>NADH</i>	290, 350 - 370	440, 460
<i>NADPH</i>	340	460
<i>FAD, Flavins</i>	420 - 450	520 - 550
<i>FMN</i>	420 - 500	520 - 570
<b><i>Vitamins</i></b>		
<i>Vitamin A</i>	327	510
<i>Vitamin K</i>	335	480
<i>Vitamin D</i>	290, 350 - 390	400 - 480
<i>Vitamin B6 compounds</i>	315, 330, 340	385, 400, 425
<i>Vitamin B12</i>	275	305
<b><i>Lipids</i></b>		
<i>Phospholipids</i>	430	500, 540
<i>Lipofuscin</i>	340 - 395	430 - 460, 540
<i>Ceroid</i>	340 - 395	430 - 460, 540
<b><i>Porphyrins</i></b>	390 - 450, 630	600 - 710




# Chromophores in the skin tissues




Fluorophores



Absorbers



In vivo



# Requirements for in vivo measurements in clinics

- Noninvasive (intact lesion)
- Reliable
- User-friendly equipment
- Fast measurement ~ 1-2 min  
(EEM needs ~18-20 min.)
- Allows to reach high sensitivity  
(presence of lesion)
- Allows to reach high specificity  
(type and stage of lesion)
- Repeatable results  
(for therapy monitoring goals)
- Sensible level of the optical signal –  
need to combine optical techniques due  
to highly pigmented cutaneous lesions  
(**MM**, pigm BCC, dysplastic nevi, etc.)

## Fluorescence

- (+) Biochemical information
- (+) High sensitivity
- (+) Repeatable
- (+) Noninvasive
- (-) Moderate specificity
- (-) Require sensitive detectors
- (-) Signal complex analysis

## Reflectance

- (+) Morphological information
- (+) Repeatable
- (+) Noninvasive
- (+) Not require sens. detectors
- (+) Pigmentation sensitive
- (-) Moderate sensitivity
- (-) Moderate sensitivity

# Procedure for excised samples studies

## **FluoroLog 3** system (HORIBA Jobin Yvon, France)

It consists of Xe lamp (200-650 nm), scanning double monochromators, and PMT detector with high performance in the region 200-800 nm.


Ethical committee approval #286/24.07.2012

1. Initial clinical observation and diagnosis;
2. Histological/cytological analysis;
3. Clinical investigations (blood, scanner, etc.) – decision for surgical treatment
4. Excision of tumours – sampling for histology and for fluorescent spectroscopy detection
5. Transport from the hospital to spectral lab in isothermal conditions and safe-keeping solution
6. Fluorescence EEM measurements– up to 2 hours after surgical removal
7. Comparison of the spectral data b/n samples and histological diagnosis


Compound	Concentration [mg/500ml]
NaCl	3680
KCl	210
Glucose	1800
Taurine	1250
Hepes	1190
Piruvic acid	275

In volume 20ml physiological solution are added 100µl  $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$  at concentration 0,1mM. pH is fixed on 7,4.

# Methods and materials




**FluoroLog 3 (HORIBA Jobin Yvon, France)**  
**and F-3000 fiber-optic module**  
**SFS regime**  
**excitation – 280-440 nm,**  
 **$\Delta\lambda = \lambda_{em} - \lambda_{exc}$ , 0 -200 nm, step 10 nm**  
**emission – 300-800 nm, step 1 nm**




# Reference data – endogenous fluorophores

Endogenous fluorophores	Excitation (nm)	Emission (nm)
<b>Amino acids</b>		
Phenylalanine	260	280
Tyrosine	275	300
Tryptophan	280	350
<b>Structural proteins</b>		
Collagen	280, 320-350, 390	370 – 440
Elastin	290 - 325	340, 400
Collagen cross-links	380 - 420	440 - 500
Elastin cross-links	320 - 360, 400	480 - 520
Keratin	380 - 400, 450 – 470	500 - 550
<b>Enzymes and co-enzymes</b>		
NADH	290, 350 - 370	440, 460
NADPH	340	460
Flavins	420 - 450	520 - 550
FMN	420 - 500	520 - 570
<b>Vitamins</b>		
Vitamin A	327	510
Vitamin K	335	480
Vitamin D	290, 350 - 390	400 - 480
Vitamin B6 compounds	315, 330, 340	385, 400, 425
Vitamin B12	275	305
<b>Lipids</b>		
Phospholipids	430	500, 540
Lipofuscin	340 - 395	430 - 460, 540
Ceroid	340 - 395	430 - 460, 540
<b>Porphyrins</b>	390 - 450, 630	600 - 710






# Skin EEM data – in vivo







Normal skin phototype II  
autofluorescence – excitation  
emission matrix

Origins of the AF signal




# Results - EEM

## EEM and steady-state autofluorescence spectra of normal tissue



## EEM and steady-state autofluorescence spectra of cancerous tissue - BCC

# Materials and methods – in clinics





## Set-up used for the initial clinical investigations


- Halogen lamp (400-900 nm) for diffuse reflectance spectroscopy
- LEDs - emission max at 365, 385, and 405 nm, 10-15 nm FWHM, 3-5 mW optical power – as excitation sources for autofluorescence spectroscopy
- Y-fiber bundle with 6 fibers for excitation light and 1- central fiber – as optical fiber probe
- USB4000 microspectrometer (USB4000, OceanOptics Inc.) 350-1000 nm detection range
- PC - storage and visualization of the spectral data




# Influences



Exc. at 365 nm




Exc. at 385 nm




- anatomic place
- skin phototype
- excitation wavelength

# Results - repeatability



unnormalized with respect to max




normalized with respect to max

Comparison of the fluorescence spectra obtained from lateral part of the forearm of six volunteers with phototype I, excitation used at 385 nm


- spectral shape is similar for all cases
- slight differences in max intensity, related to pigmentation and blood content deviations




# Non-melanoma tumors - results



BCC - Exc. at 365 nm




SCC - Exc. at 365 nm



KA – Exc. at 405 nm


# Tumor stage evaluation – initial vs. advanced



Initial BCC


*Excitation at 405 nm*

Advanced BCC



- Two BCC lesions of one patient, one of the lesions has appeared about two years before the observation; second has appeared about eight months before the light-induced fluorescence measurements carried out.
- No needs for compensation related to inter-patients differences. Intra-patient differences could be taken as negligible, due the fact that both pathologies were nearby.

# Multiple lesions – treatment planning



- Porphyrin-like signal from advanced lesions



One patient, 69 years-old - 5 BCC lesions on different stage of growth, similar size (1x1cm area) and clinical picture

Treatment decision:  
Lesions 2 and 5 – advanced stage – surgical removal and chemotherapy

Lesion 4 – intermediate stage – chemo- and radiotherapy, 2 months later

Lesions 1 and 3 – initial stage – local chemotherapy, 3 months later



# Mixed tumor – therapy failure



- 78 – years old patient
- tumor size 5 x 6 cm on the forehead
- failed Ro-therapy

# Comparison of malignant lesions' AF spectra

Fluorescence spectra of the common lesions observed, compared for two different excitation sources




MM

Pigm. BCC



# Skin reflectance

## Detection of reflectance signal



1) Light in broad spectral region penetrates in the skin


2) Tissue absorbers selectively absorb light on the different wavelengths

3) Light is scattered in the tissue volume and part of it scattered back to the surface

4) Reflectance signal consisted from specular reflectance component and diffuse back-scattered signal form the tissue volume could be detected by spectrometer




# Normal skin reflectance spectra




Main absorbers in human tissues

Normal skin reflectance spectra from the medial and lateral parts of the forearm and the palm for one patient




# Normal skin reflectance




**Skin phototype I**

**Skin phototype II**




# Reflectance of melanin-pigmented benign and malignant lesions




Reflectance spectra presented with their standard deviations of normal skin, compound nevus, dysplastic nevus and pigmented MM, averaged by lesion type for all patients

Reflectance spectra presented with their standard deviations of normal skin, pigmented, amelanotic and secondary melanoma lesions, averaged by lesion type for all patients





# Reflectance of non-melanin-pigmented benign and malignant lesions



Reflectance spectra presented with their standard deviations of normal skin, compound nevus, dysplastic nevus and pigmented MM, averaged by lesion type for all patients

Ratios chosen for differentiation and valuation between normal skin, melanin-pigmented lesions, BC lesions and hemangioma - dimensionless ratios of the reflectance values at 500, 575 and 700 nm.






Comparison	SN %	SP %	DA %
Compound nevus/ Dysplastic nevus	82,1	77,6	61,8
Dysplastic nevus/ Malignant melanoma	92,4	77,6	75,3
Normal skin/ BC papilloma	95,7	98,5	89,2
Normal skin/ BCC	94,0	98,2	86,8
BC papilloma/BCC	91,0	87,2	83,8

## Statistical values of reflectance diagnosis of skin lesions





### Algorithm for differentiation

$$R_1 = \ln(\text{norm}(500) * \text{lpigm}(700) / \text{lnorm}(700) * \text{lpigm}(500))$$

$$R_2 = \ln(\text{norm}(500) * \text{lpigm}(575) / \text{lnorm}(575) * \text{lpigm}(500))$$



# Automation of cancer diagnosis based on colorimetric transformation of cutaneous reflectance spectra




**Transformations: spectrum–CIEXYZ -HS**

# Combination - LIFS+DRS+colorimetry

	Technique	SN %	SP %	PPV %	NPV %	IS %	DA %
	LIAFS + DRS + SHΣ (3/3)	55,6	93,3	83,3	77,8	66,7	50
	LIAFS + DRS + SHΣ (2/3)	77,8	93,3	87,5	87,5	88,9	70
	LIAFS + DRS + SHΣ (1/3)	100	93,3	90	100	111,1	90


- LIAFS + DRS + SHΣ 1/3
- LIAFS + DRS + SHΣ 3/3

24 MM, DN and BN patients




# Diagnostic accuracy in clinical investigation for optical biopsy skin cancer detection

ROC – differentiation of malignant melanoma vs. melanocytic nevi



Area	p	95% CI	
		Lower	Upper
0,901	< 0,0001	0,840	0,962

ROC – differentiation of malignant melanoma vs. non-melanoma malignancies (BCC, SCC, KA, Bowen, etc.)



Area	p	95% CI	
		Lower	Upper
0,961	< 0,0001	0,915	1,007

Method and compared lesions	SE, %	SP, %	PPV, %	NPV, %	DA, %
AF – NMSC vs. benign	100	99,2	99,4	100	99,3
AF – MM vs. benign	100	99,2	97,6	100	98,4
AF – MM vs. NMSC	99,1	90,5	98,4	95,1	93,6
RS – NMSC vs. benign	86,6	41,3	68,8	67,4	69,4
RS – MM vs. benign	92,7	85,3	77,6	95,5	90,1
RS – MM vs. NMSC	92,7	99,1	97,4	97,4	96,1



# Thank you very much for your attention!

---

